212 related articles for article (PubMed ID: 38411946)
1. Oncolytic Newcastle disease virus induced degradation of YAP through E3 ubiquitin ligase PRKN to exacerbate ferroptosis in tumor cells.
Sun Y; Tang L; Kan X; Tan L; Song C; Qiu X; Liao Y; Nair V; Ding C; Liu X; Sun Y
J Virol; 2024 Mar; 98(3):e0189723. PubMed ID: 38411946
[TBL] [Abstract][Full Text] [Related]
2. Newcastle Disease Virus V Protein Degrades Mitochondrial Antiviral Signaling Protein To Inhibit Host Type I Interferon Production via E3 Ubiquitin Ligase RNF5.
Sun Y; Zheng H; Yu S; Ding Y; Wu W; Mao X; Liao Y; Meng C; Ur Rehman Z; Tan L; Song C; Qiu X; Wu F; Ding C
J Virol; 2019 Sep; 93(18):. PubMed ID: 31270229
[TBL] [Abstract][Full Text] [Related]
3. The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2.
Yang WH; Lin CC; Wu J; Chao PY; Chen K; Chen PH; Chi JT
Mol Cancer Res; 2021 Jun; 19(6):1005-1014. PubMed ID: 33707306
[TBL] [Abstract][Full Text] [Related]
4. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
5. Newcastle-disease-virus-induced ferroptosis through nutrient deprivation and ferritinophagy in tumor cells.
Kan X; Yin Y; Song C; Tan L; Qiu X; Liao Y; Liu W; Meng S; Sun Y; Ding C
iScience; 2021 Aug; 24(8):102837. PubMed ID: 34368653
[TBL] [Abstract][Full Text] [Related]
6. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
7. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
8. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
Kalyanasundram J; Hamid A; Yusoff K; Chia SL
Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment.
Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A
Virol J; 2020 May; 17(1):64. PubMed ID: 32370750
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
Zamarin D; Palese P
Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889
[TBL] [Abstract][Full Text] [Related]
11. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death.
Elankumaran S; Rockemann D; Samal SK
J Virol; 2006 Aug; 80(15):7522-34. PubMed ID: 16840332
[TBL] [Abstract][Full Text] [Related]
12. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
13. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Newcastle disease virus effects on immune response - a new issue in cancer treatment.
Kooti W; Esmaeili HGG; Farzanehpour M; Dorostkar R; Jalali Kondori B; Bolandian M
Klin Onkol; 2023; 36(2):124-129. PubMed ID: 37072246
[TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells.
Gong Y; Tang N; Liu P; Sun Y; Lu S; Liu W; Tan L; Song C; Qiu X; Liao Y; Yu S; Liu X; Lin SH; Ding C
Autophagy; 2022 Jul; 18(7):1503-1521. PubMed ID: 34720029
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells.
Jiang K; Li Y; Zhu Q; Xu J; Wang Y; Deng W; Liu Q; Zhang G; Meng S
BMC Cancer; 2014 Jul; 14():551. PubMed ID: 25078870
[TBL] [Abstract][Full Text] [Related]
17. Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53.
Abd-Aziz N; Stanbridge EJ; Shafee N
J Gen Virol; 2016 Dec; 97(12):3174-3182. PubMed ID: 27902314
[TBL] [Abstract][Full Text] [Related]
18. Newcastle disease virus as an oncolytic agent.
Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
[TBL] [Abstract][Full Text] [Related]
19. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells.
Mansour M; Palese P; Zamarin D
J Virol; 2011 Jun; 85(12):6015-23. PubMed ID: 21471241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
